Videos

This is the last day of a joint meeting of the FDA’s Arthritis and Drug Safety and Risk Management Advisory Committees. At the end of the three-day forum the 32-member panel had recommended …

At a joint meeting of the Arthritis and Drug Safety and Risk Management Advisory Committees, experts discussed the safety of arthritis drugs called “COX-2” inhibitors. Dr. Anne Trontell gave…

At a joint meeting of the Arthritis and Drug Safety and Risk Management Advisory Committees, members discussed the safety of drugs called “COX-2” inhibitors, such as Vioxx and Celebrex. Dr. …

The Food and Drug Administration’s Arthritis and Drug Safety and Risk Management Advisory Committees continued discussions in their joint meeting on possible safety of risks of “COX-2” inhib…

Committee members heard public comments made by representatives of arthritis-related and consumer organizations, as well as the general public, on the safety of various medications designed …

Physicians spoke at a meeting to assess the safety records of arthritis drugs. Representatives for the drug Lumiracoxib and for the Food and Drug Administration spoke. They also responded to…

Physicians spoke at a meeting to assess the safety records of arthritis drugs such as Vioxx and Celebrex. They also talked about recent uses of the class of drugs, the medical and scientific…

Dr. Villalba and others spoke at a meeting to assess the safety records of arthritis drugs. They talked about testing and approval of the drug Vioxx and its subsequent use by American consum…

Physicians spoke at a meeting to assess the safety records of arthritis drugs. Representatives for the drugs Celebrex, Bextra, Parecoxib, and Naproxen spoke as did representatives for the Fo…

A joint meeting of the Food and Drug Administration’s Arthritis and Drug Safety and Risk Management Advisory Committees held a forum on the safety of “COX-2” inhibitors. The function of the …